Nucleix
Updated: January 06, 2026
Chris Hibberd, CEO
Country: Israel | Funding: $83M (+)
Founded: 2008
Website: https://nucleix.com/
Nucleix is developing liquid biopsy technology for the early detection of cancer. Its first product - Bladder EpiCheck test is certified for the diagnosis of primary and recurrent bladder and upper urinary tract cancer. This in vitro diagnostic device detects DNA methylation patterns in urine associated with urothelial carcinoma. It is intended for use as non-invasive method for monitoring tumor recurrence in conjunction with standard diagnostic procedures. The test analyzes small, disease-specific changes in DNA methylation markers, enabling the detection of cancer. The test has demonstrated high sensitivity (91%) for high-grade tumors, which are important to detect because they are aggressive and, if not treated immediately, can progress to invasive cancer. The company is also developing Lung EpiCheck to detect lung cancer at an early stage in high-risk individuals using a simple blood test.
Founded: 2008
Website: https://nucleix.com/
Nucleix is developing liquid biopsy technology for the early detection of cancer. Its first product - Bladder EpiCheck test is certified for the diagnosis of primary and recurrent bladder and upper urinary tract cancer. This in vitro diagnostic device detects DNA methylation patterns in urine associated with urothelial carcinoma. It is intended for use as non-invasive method for monitoring tumor recurrence in conjunction with standard diagnostic procedures. The test analyzes small, disease-specific changes in DNA methylation markers, enabling the detection of cancer. The test has demonstrated high sensitivity (91%) for high-grade tumors, which are important to detect because they are aggressive and, if not treated immediately, can progress to invasive cancer. The company is also developing Lung EpiCheck to detect lung cancer at an early stage in high-risk individuals using a simple blood test.
